APC/PIK3CA mutations and β-catenin status predict tankyrase inhibitor sensitivity of patient-derived colorectal cancer cells.

Mingjue ChenTetsuo MashimaTaichi OishiYukiko MuramatsuYosuke SetoManabu TakamatsuNaomi KawataShun MorinoAyane NakamuraSaori InabaXunmei YuanKohei MaruyamaMai SuzukiAyana SatoHaruka YoshidaMyung-Kyu JangAnna MizutaniKengo TakeuchiKensei YamaguchiFumiyuki ShiraiSatoshi Nagayama Ryohei Katayama Hiroyuki Seimiya

Published in: British journal of cancer (2023)

APC/PIK3CA mutations and β-catenin predict the sensitivity of APC-mutated CRC PDCs to tankyrase inhibitors. These observations may help inform the strategy of patient selection in future clinical trials of tankyrase inhibitors.

Keyphrases

clinical trial
epithelial mesenchymal transition
cell proliferation
case report
protein kinase
current status
signaling pathway
phase iii